Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Non-small Cell Lung Cancer Metastatic × aumolertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 9 Non-small Cell Lung Cancer Metastatic 1 NSCLC 1 Brain Neoplasms 1 Advanced Non-small Cell Lung Cancer 1

Interventions

tusamitamab ravtansine 1 aumolertinib 1 Paclitaxel 1 Docetaxel 1 Carboplatin 1 Bevacizumab 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05800223 2023-04-05

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Shanghai Cancer Hospital, China

Phase 3 Recruiting

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡